PHARMACOLOGICAL MODULATION OF PICRYL CHLORIDE-INDUCED CONTACT-DERMATITIS IN THE MOUSE

被引:16
作者
LAVAUD, P [1 ]
RODRIGUE, F [1 ]
CARRE, C [1 ]
TOUVAY, C [1 ]
MENCIAHUERTA, JM [1 ]
BRAQUET, P [1 ]
机构
[1] INST HENRI BEAUFOUR,DEPT IMMUNOL,1 AVE TROP,F-91952 LES ULIS,FRANCE
关键词
D O I
10.1111/1523-1747.ep12478438
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
A biphasic response of ear swelling was observed 2 h and 24 h after application of the antigen to picryl chloride-sensitized Balb/c mice. A platelet-activating factor (PAF) antagonist, BN 52063, or the anti-inflammatory drug, betamethasone, applied topically or injected subcutaneously, inhibited in a dose-dependent fashion the antigen-induced increase in ear thickness observed after 24 h. In addition, BN 52063 and betamethasone presented a synergistic effect when administered in vivo simultaneously and subcutaneously. Indomethacin administered subcutaneously at the time of the antigen challenge significantly potentiated the early swelling phase and inhibited the late one. In contrast, the inhibitors of histamine and serotonin, ketotifen and methysergide, respectively, modulated mostly the early, and to a lower extent the late phase when administered at the time of antigen challenge. In contrast, none of these drugs inhibited the late phase reaction when administered 4 h after the antigen. A significant eosinophil and mononuclear-cell ear infiltrate was observed following topical application of the antigen, a phenomenon that was markedly reduced by either BN 52063 or betamethasone. These results demonstrate the effectiveness of PAF antagonists, either alone or in association with glucocorticosteroids, in experimental CD, the modulation of the infiltration of eosinophils and mononuclear cells possibly explaining part of the inhibitory action of these drugs.
引用
收藏
页码:101 / 105
页数:5
相关论文
共 18 条
[1]  
ASKENASE PW, 1983, J IMMUNOL, V131, P2687
[2]   IS THERE A CASE FOR PAF ANTAGONISTS IN THE TREATMENT OF ISCHEMIC STATES [J].
BRAQUET, P ;
PAUBERTBRAQUET, M ;
KOLTAI, M ;
BOURGAIN, R ;
BUSSOLINO, F ;
HOSFORD, D .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1989, 10 (01) :23-30
[3]  
BRAQUET P, 1989, J LIPID MEDIATOR, V1, P75
[4]  
BRAQUET P, 1987, Drugs of the Future, V12, P643
[5]  
BRAQUET P, 1987, PHARMACOL REV, V39, P97
[6]  
CALTMAN L, 1981, J CLIN INVEST, V67, P28
[7]  
CAMP RDR, 1989, J INVEST DERMATOL, V92, pS78
[8]  
CAPRON M, 1988, GINKGOLIDES CHEM BIO, P205
[9]   CORTICOSTEROIDS AND LYMPHOID-CELLS [J].
CLAMAN, HN .
NEW ENGLAND JOURNAL OF MEDICINE, 1972, 287 (08) :388-+
[10]  
CRIJNS MB, 1984, CONTACT DERMATITIS, V11, P108